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Background. FoxP3 is the most reliable marker for regulatory T cells
which play an important role in maintaining tolerance of renal
allograft. Recently, FoxP3 gene polymorphisms have been reported to
be associated with graft survival in renal transplantation.
Methods. We analyzed the association of FoxP3 polymorphisms
(rs3761548A/C, rs2280883C/T, rs5902434del/ATT, and rs2232365A/G)
and graft outcome by polymerase chain reaction with
sequence-specific primers (PCR-SSP) on 231 adult renal
transplantation recipients performed during the period of 1996-2004 in
Seoul National University Hospital.
Results. Patients with rs2280883 TT genotype showed lower acute
rejection rate compared to CC or CT genotype (26.9% vs 53.3%, P =
0.038). Patients with rs3761548 CC genotype showed better graft
survival compared to AC or AA genotype (log rank test, P = 0.03).
Patients with rs2280883 TT genotype showed better graft survival
compared to CT or CC genotype (P = 0.02).
ii
Patients with rs3761548 CC genotype showed lower rate or recurrence
of underlying glomerular disease compared to AC or AA genotype (P
= 0.01).
Conclusion. FoxP3 polymorphism rs3761548 CC and rs2280883 TT
genotypes were associated with superior graft outcome of renal
transplantation in Koreans. Further studies are needed in larger
number of patients.
……………………………………………………………………
keywords : FoxP3, single nucleotide polymorphism,
renal transplantation, graft survival
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Improved pre-transplantation evaluation and the development of
post-transplantation immunosuppressive therapy have led to a marked
improvement in short-term graft survival in renal transplantation.
However, long-term graft survival remains unsatisfactory [1].
Immunologic responses of patients play pivotal roles in graft rejection
or recurrence of underlying renal disease. Regulatory T cells (Tregs)
promote a state of antigen specific peripheral tolerance by suppressing
activation and expansion of T effector cells, as reported in experimental
models [2, 3]. Therefore they play an important role in maintaining
self-tolerance and in regulating graft rejection and graft-versus-host
disease [4, 5].
Foxkhead box P3 (FoxP3) is a member of Forkhead box protein, a
family of transcription factors that play important roles in regulating
the expression of genes [6]. FoxP3 involves in immune system
reponses, appearing as a master regulator of the regulatory pathway in
the development and function of regulatory T cells [7, 8].
FoxP3 is more specific for Treg cells than CD25 or CD45RB, although
it is not completely exclusive. CD4+ effector T cells without
suppressive activity may still upregulate FoxP3 expression upon
activation. Therefore, FoxP3 cannot be considered as a unique symbol
of human Treg cells [9]. However, Treg cells that express FoxP3 are
critical in the transfer of immune tolerance, especially self-tolerance.
Constitutive expression of FoxP3 is the decisive factor driving the
immunosuppressive function of mouse and human Treg cells [10].
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Therefore, FoxP3 remains the most reliable marker for Treg [11].
FoxP3 gene polymorphisms, which could affect the function and
quantity of FoxP3 molecule, and thus result in the Treg function
defects, have been associated with various autoimmune diseases [11,
12].
For renal transplantation, the impact of FoxP3+ Tregs on graft
outcomes seems conflicting in previous reports [13-19]. In some study,
the presence of intragraft Tregs have been associated with favorable
renal allograft outcome [13, 14]. The FoxP3+ Treg/CD3+ T cell ratio
positively correlated with graft function at 2 years after transplantation
[13]. These cells could direct a FoxP3-induced immune response toward
suppression of T effector cells, promoting renal graft acceptance with
improved function. Lower level of intragraft FoxP3 mRNA predicts
progression in renal transplants with borderline change [15]. The mRNA
levels of FoxP3 in peripheral blood were higher in patients with
operational tolerance or stable kidney graft function compared to
patients with chronic rejection [16, 17]. However, other groups reported
that mRNA for FoxP3 in the urine of recipients with acute rejection
was higher than recipients with normal biopsy [18] and association of
higher density of FoxP3+cells with worse graft outcome in recipients
with acute cellular rejection [19].
Recently, an association between FoxP3 gene polymorphisms and graft
outcome has been reported also with conflicting results [20-22].
Therefore, we analyzed the association of four FoxP3 single nucleotide
polymorphisms (SNPs) (rs3761548 A/C, rs2280883 C/T, rs5902434
3
del/ATT, and rs2232365 A/G) with graft outcome in renal
transplantation.
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2. MATERIALS AND METHODS
2.1. Subjects
This study included 231 renal transplantation cases performed between
January 1996 and December 2004 at the Seoul National University
Hospital. The baseline characteristics of the 231 kidney transplant
recipients are shown in Table 2. Residual DNA samples were collected
after routine preoperative tests for HLA genotype. DNA samples from
195 healthy Korean studied in our previous cohort were used [23].
Samples were preserved at -70℃ prior to the experiments performed
for this study. The following characteristics were collected: age and
gender of recipient; age and gender of donor; type of donor (living vs
cadaveric donor); primary renal disease causing end-stage renal disease;
number of HLA mismatches; number of HLA-DR mismatches;
crossmatch result at the time of transplantation; duration of
hemodialysis; type of immunosuppression; time of transplantation;
occurrence and time point of biopsy-proven acute rejection; recurrence
of primary renal disease; 1-, 3-, 5-, 10-year creatinine levels
post-transplantation; occurrence and time of graft failure, defined as
graft nephrectomy or return to hemodialysis. The study protocol was
the Declaration of Helsinki and approved by the institutional review
board of Seoul National University Hospital (IRB No. 1306-121-501).
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2.2. Analysis of FoxP3 Gene SNPs
A total of 426 DNA samples were extracted from the peripheral blood
of patients and controls by using the LaboPass Genomic DNA
Extraction Kit (COSMO, Seoul, Korea) or QuickGene DNA whole blood
kit (Fujifilm, Tokyo, Japan) and maintained at -80℃ prior to being used
for these analyses. Four FoxP3 polymorphisms (rs3761548 A/C,
rs2280883 C/T, rs5902434 del/ATT, and rs2232365 A/G) were analyzed
by polymerase chain reaction with sequence-specific primers
(PCR-SSP) with some modification [24] (Table 1). Modification includes
division of existing primer sequences, slight shift of position, and
application of inosine hinges to improve specificity of target
polymorphisms. PCR was performed by 40 μL reaction mixture
containing 40 ng DNA, 0.2 mM of each primer, 0.8 μL of 10 mM
dNTP, 2.0 mM MgCl2, 1.0 U Taq DNA polymerase (Roche applied
science, Basel, Switzerland), and 4 μL of 10× reaction buffer. The PCR
protocol consisted of an initial denaturation step at 95℃ for 5 min; 35
cycles of denaturation at 95℃ for 30 sec, annealing (temperatures
detailed in Table 1) for 30 sec, and extension at 72℃ for 30 sec, and a
final extension step at 72℃ for 5 min.
6
SNP AT (℃) Sequence (5’ → 3’)
















Table 1. Sequence specific primers of FoxP3 polymorphisms
Abbreviations: SNP, single nucleotide polymorphism; AT, annealing temperature; F, forward; R, reverse; del,
deletion; I, inosine.
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2.3. Processing reference sequence data
The Korean Reference Genome database (KRGDB) were used as
reference population [25]. KRGDB is a database analyzed 622 Korean
individuals by whole genome sequencing using Illumina Hiseq2000
sequencer. We searched for corresponding rs number in our study
and drew up major and minor allele frequency of three SNVs
(rs3761548, rs2280883 and rs2232365) and one insertion/deletion variant
(rs5902434). Genotype frequencies of these SNPs or indel of FoxP3
were calculated by a simple allele counting method.
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2.4. Predicting the effect of intron variant
For the possibility of epigenetic alteration of intronic variant,
rs2280883, the likely consequences of the splice site mutation on




Differences of allele frequency and genotype frequency were
compared using a 2-sided Chi-square test or Fisher’s exact test, as
appropriate. The logistic regression analysis was performed to find
the independent association between presence/absence of alleles and
disease while adjusting for the covariates. The odds ratio (OR) was
calculated using a 95% confidence interval. Univariate and
multivariate Cox proportional hazard regression models were used to
estimate the crude and adjusted hazard ratios (HRs) and their 95%
CIs. Multivariate analysis was performed to confirm the association
between FoxP3 polymorphism and graft outcome (acute rejection or
all rejection) after considering confounding factors by univariate
analysis. Variables with P < 0.25 from univariate logistic regression
analyses were included in multivariate analysis, which performed by
backward stepwise selection. Death-censored graft survival was
analyzed using the Kaplan-Meier method and the log-rank test. SPSS
for Windows version 18.0 (SPSS, Chicago, IL, USA) was used for
statistical analysis.
Allelic and Genotypic frequencies of SNPs of FoxP3 were calculated
by a simple allele/genotype counting method. Allelic distribution in
cases and controls [23] was compared by odds ratio statistics using
MedCalc Statistical Software version 16.4.3 (MedCalc Software bvba,
Ostend, Belgium; https://www.medcalc.org; 2016). The alleles and
corresponding homozygous genotypes with major frequency in the
control group have been selected as reference (OR = 1). A P value
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of < 0.05 was considered statistically significant. Linkage
disequilibrium (LD), expected heterozygosity were performed using
Arlequin software ver.3.5.2.2. [28]. Significance of difference between
groups was analysed using Chi square test.
The variance in the haplotypes and Hardy-Weinberg equilibrium




3.1. Characteristics of the study population
The baseline characteristics of the 231 kidney transplant recipients
are shown in Table 2 and Table 3. Rs3761548 CC and rs2280883 TT
genotypes showed significantly better survival (P = 0.038 and P =
0.032, respectively).
Diabetic nephropathy (DN) composes only 5.2% (10/194) causes of
renal transplantation. Sixty percent (6/10) of DN recipients and 26.5%
(50/189) of non-diabetic nephropathy (NDN) recipients experienced
acute rejection during follow up. Sixty percent (6/10) of DN recipients
and 36.0% (68/189) of NDN recipients underwent any kinds of
rejection episodes. Acute rejection and all rejection hazard ratio for
DN is 5.05 and 2.53 times that of NDN (P = 0.001 and 0.039,
respectively) (data not shown). Consequently DN recipients
experienced shorter graft survival (P = 0.001).
Of all recipients, 28.6% went through acute rejection, and their graft
survival was also significantly shorter (P < 0.001). Otherwise, no
significant differences in age, primary disease, human leukocyte
antigen mismatches, renal transplantation, Anti-HLA immunisation,
post-transplantation serum creatinine level or immunosuppressant
regimen were found between patients of either SNP groups.
We performed mutivariate analysis on four variates above, however




(n = 231) P value*
Recipient
Median age (IQR) [years] 38 (30-46) 0.329
Gender [M/F] 142/89 0.967
Graft failure [GF-/GF+] 208/23 n/a
FoxP3 polymorphism
rs3761548 [AC or AA/CC]
rs2280883 [CT or CC/TT]
rs5902434 [ATT/ATT, del/del or del/ATT]












Induction therapy [-/+] 199/32 0.445
Donor
Median age (IQR) [years] 37 (27-48) 0.935
Gender [M/F] 224/7 0.086
Transplant
Graft origin [LD/CD] 203/28 0.904









Class I 36 (26.9%) 0.230






Table 2. Characteristics of the study population and univariate Cox
proportional hazards regression analysis with regard to graft survival
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* univariate Cox regression analysis
†56 (24.1%) cases could not be defined as either primary disease category.
‡All 231 cases were negative for cytotoxic crossmatch and two cases were
positive only for T-cell flowcytometric crossmatch.
§ 98 (42.2%) cases do not have PRA results at the time of transplantation.
Abbreviations: IQR, interquartile range; M, male; F, female; DN, diabetic
nephropathy; NDN, nondiabetic nephropathy; n/a, not available; LD, living











































































































Table 3. Immunosuppressive regimen of the 231 kidney transplant recipients.




HR (95% CI) P
RFS
HR (95% CI) P
RcFS
HR (95% CI) P





































Table 4. Multivariate analysis of factors related with graft survival in renal transplantation.
Abbreviations: OS, overall survival; RFS, rejection free survival; RcFS, recurrence free survival; HR, hazard ratio; CI,
confidence interval; DN, diabetic nephropathy; NDN, non-diabetic nephropathy
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3.2. Comparison of gene frequency with Korean
population database
For the frequencies of alternative alleles of rs3761548 and rs5902434
were found to be significantly high in kidney recipient group as
compared to controls indicating genetic predisposition of impaired
renal function (P < 0.01 and 0.02; OR = 1.55 and 1.29; 95% CI =
1.12-2.13 and 1.03-1.62, respectively; Table 5).
For rs2280883 and rs2232365, the frequencies of alternative alleles
were significantly low in kidney recipient group as compared to
controls (P < 0.01 and 0.03; OR = 0.48 and 0.78; 95% CI = 0.34-0.69














rs3761548 C A 1022 (82.4) 392 (87.9) 1.55 (1.12-2.13) < 0.01
rs2280883 T C 208 (16.8) 41 (8.9) 0.48 (0.34-0.69) < 0.01
rs5902434 ATT del 750 (60.5) 307 (66.5) 1.29 (1.03-1.62) 0.02
rs2232365 T C 484 (39.0) 154 (33.3) 0.78 (0.62-0.98) 0.03
Table 5. Comparison of allelic frequency of FoxP3 polymorphisms in recipients with Korean cohort.
Abbreviations: AF, allelic frequency; OR, odds ratio.
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3.3. Linkage disequilibrium and haplotype-based
association analysis
LD analysis revealed strong linkage between rs5902434, rs2232365
and rs3761548 in the FoxP3 gene (r2 = 0.98, D’= 1.00 ). Weak
correlation was revealed between rs2280883 and rs5902434 in the
FoxP3 gene (r2 = 0.20, D’ = 1.00). Therefore two representative SNP
rs2280883 and rs5902434 was included in subsequent genetic
analyses. Expected heterozygosity is 0.16 for rs2280883, reflecting an
excess of homozygotes. Expected heterozygosity for rs5902434 and
rs2232365 is 0.45 and 0.45, respectively. Theta(H) under the
infinite-allele model is 0.19 for rs2280883, 0.81 for rs5902434 and 0.80
for rs2232365 (Figure 1).
LD analysis for FoxP3 was duplicated using both Arlequin 3.5.2.2.
and Haploview 4.2. Haplotype blocks were used to measure LD.
Samples from kidney allograft recipients exhibited substantial LD
amongst themselves (Figure 2). We detected one LD block within
FoxP3. As shown in Figure 2, the number and the color of the
square indicates D’ and the gray square denotes D’ = 1. The gradient
colors demonstrate the strengths of the LDs of the tag SNPs. The
LD block 1 haplotype was formed by three tag SNPs (rs2232365:T,
rs3761548:A and rs5902434:del), which had nominally significantly
different frequencies in the two groups (P value <0.001)(Table 6).
Other haplotypes were not significantly associated between kidney
allografts and recipients. All SNPs studied but rs2280883 participated
in forming haplotypes (Figure 2 and Table 6).
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Figure 1. Expected heterozygosity (A) and theta (H) (B) at
rs2280883, rs5902434 and rs2232365. rs2280883 shows low genetic
diversity and polymorphism. rs5902434 and rs2232365 show rich and
even genetic diversity. Values are similar because the segregation of
two locus (figure not shown).
20
Figure 2. Linkage disequilibrium of FoxP3 polymorphisms (A) All






T-A-del 0.061 0.227 15.314 < 0.001
G-A-del 0.312 0.212 3.627 0.25
G-G-ATT 0.620 0.561 1.241 0.50
Table 6. Association of haplotype frequencies of FoxP3 polymorphisms with kidney recipients.
Abbreviation: del, deletion
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3.4. Association of FoxP3 polymorphisms with
graft rejection
The frequency of acute rejection (AR) in rs3761548 AC or AA
genotype showed a tendency of increase compared to CC genotype
(45.5% vs. 26.8%, P = 0.082) (Table 7). The frequency of acute
rejection (AR) in rs2280883 CT or CC genotype showed significantly
increase compared to TT genotype (53.3% vs. 26.9%, P = 0.038)
(Table 7). In univariate analysis, rs2280883 CC or CT genotype was
a risk factor for acute rejection compared to TT genotype (P = 0.04).
Other polymorphisms showed no association with acute rejection.
Chronic or all rejection is not associated with any FoxP3
polymorphisms analyzed in this study.
Of the four SNPs analyzed, rs3761548 and rs5902434 were
reconstructed a block combined of two haplotypes (G-ATT and
A-del). Association between haplotypes and rejection episodes (acute


































































































































Table 7. Association of FoxP3 polymorphisms with graft rejection
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Abbreviations: SNP, single nucleotide polymorphism; AR, acute







G-ATT 60.8 61 (61.0) 39 (39.0) 0.007 0.933
A-del 39.2 39 (39.0) 61 (61.0) 0.007 0.933
Chronic rejection
G-ATT 60.8 62 (61.1) 40 (38.9) 0.001 0.979
A-del 39.2 40 (38.9) 62 (61.1) 0.001 0.979
Table 8. Association of FoxP3 haplotypes of rs3761548 and rs5902434 with acute or chronic graft rejection
Abbreviations: HF, haplotype frequency; del, deletion
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3.5. Graft survival and FoxP3 polymorphism
Kaplan-Meier analysis was used to examine the relationships between
FoxP3 SNPs and graft survival. Patients with rs3761548 CC genotype
showed better graft survival compared to AC or AA genotype (log
rank test, P = 0.03). Patients with rs2280883 TT genotype showed
better graft survival compared to CT or CC genotype (P = 0.02)
(Figure 3A and B). The mean and 95% CI of time to graft failure for
the rs3761548 CC and AC or AA groups were 174.9 ± 3.7 (95% CI:
167.8-182.1) months and 152.0 ± 14.8 (95% CI: 123.0-181.0) months,
respectively; For the rs2280883 TT and CT or CC groups were 174.1
± 3.6 (95% CI: 167.0-181.3) months and 141.3 ± 16.0 (95% CI:
110.0-172.6) months, respectively.
Two haplotypes reconstructed from rs3761548 and rs5902434 shows
no association with graft failure (P = 0.763).
27
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Figure 3. Kaplan-Meier survival analysis of graft survival and
FoxP3 polymorphism (A) rs3761548 A/C, (B) rs2280883 C/T, (C)
rs5902434, and (D) rs2232365. (A) Patients with rs3761548 CC
genotype (n = 209) showed better graft survival than those with AC
or AA genotype (n = 22) (log rank test, P = 0.03). (B) Patients with
rs2280883 TT genotype (n = 216) showed better graft survival than
those with CT or CC genotype (n=15) (P = 0.02).
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Figure 4. Kaplan-Meier survival analysis of graft survival and
FoxP3 haplotypes of rs3761548 and rs5902434. Neither haplotype
showed association with graft survival (log rank test, P = 0.960).
Ambiguous heterozygotes were excluded from analysis (n = 30).
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3.6. Recurrence of underlying glomerular disease
posttransplant and FoxP3 polymorphism
Relationship between FoxP3 polymorphism and recurrence of
underlying glomerular disease was also analyzed by Kaplan-Meier
survival analysis. Patients with rs3761548 CC genotype showed lower
rate of recurrence of underlying glomerular disease compared to AC
or AA genotype (P = 0.01) (Figure 4). The mean and 95% CI of
time to recurrence of underlying glomerular disease for the rs3761548
CC and AC or AA groups were 180.9 ± 3.0 (95% CI: 175.1-186.8)
months and 140.5 ± 15.3 (95% CI: 110.4-170.5) months, respectively.
Two haplotypes reconstructed from rs3761548 and rs5902434 shows
no association with recurrence of underlying disease (P = 0.308).
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Figure 5. Kaplan-Meier survival analysis of recurrence of underlying
glomerular disease posttransplant and FoxP3 polymorphism (A)
rs3761548 A/C, (B) rs2280883 C/T, (C) rs5902434, and (D) rs2232365.
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Longer recurrence-free period was observed for genotype with CC
homozygote as compared to genotypes with A allele for rs3761548 (






G-ATT 71.2 85 (90.4) 9  (9.6)
1.038 0.31
A-del 28.8 32 (84.2) 6 (15.8)
Table 9. Association of FoxP3 haplotypes of rs3761548 and rs5902434 with the recurrence of underlying
disease.
Abbreviations: HF, haplotype frequency; del, deletion
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3.7. Posttransplant infection and FoxP3
polymorphism
For rs5902434, recipients with null allele showed marginal
significance of higher posttransplant infection, regardless of pathogen
(n = 35, 15.2%) than recipients without null allele (n = 5, 2.2%) (OR
= 2.69, 95% CI = 1.00-7.23, P = 0.05). Recipients with rs2232365 A
allele also showed marginal significance of higher posttransplant
bacterial infection (n = 35, 15.2%) than recipients without A allele (n
= 5, 2.2%) (OR = 2.69, 95% CI = 1.00-7.23, P = 0.05) (Table 10).
Same finding was observed with all posttransplant bacterial infection
for rs 5902434 and rs2232365 (Table 10).
No association between any FoxP3 polymorphisms and
posttransplant infection by other kinds of pathogen (virus,




All infection (%) OR
(95% CI) P(+) (-)
rs3761548C/T
CC 90 (43.1) 119 (56.9) 1.10
(0.46-2.66)
0.83
AC or AA 10 (45.5) 12 (54.5)
rs2280883C/T
TT 6 (40.0) 9 (60.0) 1.16
(0.40-3.37)
1.00
CC or CT 94 (43.5) 122 (56.5)
rs5902434
del/ATT
del/del or del/ATT 35 (15.2) 138 (59.7) 2.69
(1.00-7.23)
0.05
ATT/ATT 5 (2.2) 53 (22.5)
rs2232365A/G GG 5 (2.2) 53 (22.5) 2.69
(1.00-7.23)
0.05
GA or AA 35 (15.2) 138 (59.7)
Table 10. Patients with posttransplant infection according to FoxP3 polymorphism.




Bacterial infection (%) OR
(95% CI) P(+) (-)
rs3761548C/T
CC 37 (17.7) 172 (82.3) 0.73
(0.21-2.61)
0.77
AC or AA 3 (13.6) 19 (86.4)
rs2280883C/T
TT 1 (6.7) 14 (93.3) 3.09
(0.39-24.16)
0.48
CC or CT 39 (18.1) 177 (81.9)
rs5902434
del/ATT
del/del or del/ATT 35 (20.2) 138 (79.8) 2.69
(1.00-7.23)
0.05
ATT/ATT 5 (8.6) 53 (91.4)
rs2232365A/G
GG 5 (8.6) 53 (91.4) 2.69
(1.00-7.23)
0.05
GA or AA 35 (20.2) 138 (79.8)
Table 11. Patients with posttransplant bacterial infection according to FoxP3 polymorphism.




Viral infection (%) OR
(95% CI) P(+) (-)
rs3761548C/T CC 40 (19.1) 169 (80.9) 1.24
(0.43-3.57)
0.78
AC or AA 5 (22.7) 17 (77.3)
rs2280883C/T TT 3 (20.0) 12 (80.0) 0.97
(0.26-3.58)
1.00
CC or CT 42 (19.4) 174 (80.6)
rs5902434
del/ATT
del/del or del/ATT 33 (19.1) 140 (80.9) 1.11
(0.53-2.32)
0.85
ATT/ATT 12 (20.7) 46 (79.3)
rs2232365A/G
GG 12 (20.7) 46 (79.3) 1.11
(0.53-2.32)
0.85
GA or AA 33 (19.1) 140 (80.9)
Table 12. Patients with posttransplant viral infection according to FoxP3 polymorphism.




Mycobacterial infection (%) OR
(95% CI) P(+) (-)
rs3761548C/T
CC 5 (2.4) 204 (97.6) NA 1.00
AC or AA 0 (0.0) 22 (100.0)
rs2280883C/T
TT 0 (0.0) 15 (100.0) NA 1.00
CC or CT 5 (2.3) 211 (97.7)
rs5902434
del/ATT
del/del or del/ATT 5 (2.9) 168 (97.1) NA 0.33
ATT/ATT 0 (0.0) 58 (100.0)
rs2232365A/G
GG 0 (0.0) 58 (100.0) NA 0.33
GA or AA 5 (2.9) 168 (97.1)
Table 13. Patients with posttransplant mycobacterial infection according to FoxP3 polymorphism.








rs3761548C/T CC 2 (1.0) 207 (99.0) 4.93
(0.43-56.66)
0.26
AC or AA 1 (4.5) 21 (95.5)
rs2280883C/T TT 0 (0.0) 15 (100.0) NA 1.00
CC or CT 3 (1.4) 213 (98.6)
rs5902434
del/ATT
del/del or del/ATT 2 (1.2) 171 (98.8) 1.50
(0.13-16.85)
1.00
ATT/ATT 1 (1.7) 57 (98.3)
rs2232365A/G GG 1 (1.7) 57 (98.3) 1.50
(0.13-16.85)
1.00









TAATA/TAATA 1 (1.7) 57 (98.3)
Table 14. Patients with posttransplant fungal infection according to FoxP3 polymorphism.
Abbreviations: OR, odds ratio; del, deletion
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3.8. In-silico analysis of the intron variant on
splicing efficiency of FoxP3 polymorphism
The Netgene2 splice site prediction program comparing the
wild-type FoxP3 sequence, NC_000023.11:g.49252667C, with the
NC_000023.11:g.49252667T allele scored the likelihood of the canonical
splice site as being active abour 95% and the variant site with the
substituted T was abour 95%, similarly (Figure 5).
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Figure 6. NetGene2 graphics output of rs2280883 intron variant
prediction with (A) C allele, (B) T allele; the top part of "coding" is
the activity of an ensemble of coding predicting networks, a cyan
impulse is a prediction that has been discarded during the refinement,
and a magenta colored impulse is a prediction that has been changed
by the rule based system. Both graphs shows similar pattern and
score (data not shown).
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4. DISCUSSION
In our study, rs3761548 AA genotype was associated with inferior
graft survival and recurrence of primary renal disorders. Rs3761548
AA genotype was associated with psoriasis [30], unexplained
recurrent spontaneous abortion in Chinese [31], and intractability of
Graves’ disease in Japanese [32]. Recently, association of AA
genotype with allograft rejection was reported in renal transplantation
in Chinese [20] and in Indian [22], which are somewhat similar to our
findings. Polymorphisms of FoxP3 gene promoter may alter the
binding specificity of transcription factors and are relevant to
initiating transcription, therefore, might affect the function or quantity
of Treg [33]. Oda et al. [12] indicted that rs3761548 AA genotype
leads to a loss in binding with E47 and c-Myb, leading to defective
transcription of FoxP3. Qiu et al. [20] proved that patients with AA
genotype were more prone to allograft rejection in renal
transplantation and the function of Treg in patients with AA
genotype is weaker than that of CC genotype.
In our study, rs2280883 with C allele was associated with higher
acute rejection event; rs2280883 CC genotype was also associated
with inferior graft survival. Although there is no article elucidating
an association of rs2280883 and renal disease so far, several studies
which elicited clinical effects of rs2280883 polymorphisms has been
carried out. Analysis of the rs2280883 CC genotype was increased in
infertile women with idiopathic infertility in Brazil [34] and Graves’s
disease in China [35]. The rs2280883 variant was associated with
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susceptibility to systemic sclerosis in Italia [36], and its genotypic
frequency exhibited significant differences in patients with primary
biliary cirrhosis [37]. The mutant TT genotype was found to be more
frequent among patients with hepatitis B-related hepatocellular
carcinoma [38]. In our study, rs2280883 polymorphism was not related
with chronic rejection. There is consistent study result that also
suggest the association of FoxP3 polymophism and acute rejection
[22]. But these are somewhat different finding with previous studies
because FoxP3+Treg cells are more involved in chronic rejection
regardless subtle or obvious [39].
Polymorphisms of other genes which are relevant with host immune
responses such as FasL or IL-17 have been reported [40, 41]. Further
studies are needed in larger number of patients and in other ethnic
groups to confirm the association of rs2280883 CC genotype with
clinical outcome of renal allograft.
Although there have been a few studies regarding the effects of
FoxP3 polymorphisms on infection, it is sufficiently inferable by
mechanism FoxP3 works on immune system. Piao et al. suggested
that FoxP3 polymorphism at rs3761548 A allele may be associated
with lower postplant CMV infection in allo-HSCT recipients [42].
This finding is consistent with our results, excluding the pathogen.
Of our SNPs studied, rs2280883 is the only intron variant. which is
located in intron2 (NC_000023.11:g.49252667T>C). However it shows
statistically significant association with graft survival. To elucidate
this, we performed in-silico analysis. The variant is at the 902th base
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pair of the splice junction, it is theoretically unlike that T>C change
may cause splicing defect. However, we presented an evidence that
rs2280883C>T is associated with graft outcome. Therefore rs2280883
may not be a pathogenic variant but in linkage disequilibrium with
another pathogenic variant. However, this result is merely
computational prediction, and additional studies are necessary to
confirm the FoxP3 expression level, rather than simple splicing
prediction. RT-PCR of transcripts from peripheral Treg cells can be
the method.
Expression level of FoxP3 is largely determined by epigenetic
regulation [43]. Treg cells possess specific epigenetic features. For
example, DNA hypomethylation is specifically observed at Treg
signature gene loci, such as FoxP3, Ctla4, Ikzf4, and Ikzf2 [44] and
permissive histone marks are specifically present in Treg cells at the
FoxP3 promoter region[45]. In addition, DNA hypomethylation at
FoxP3 CNS2 (conserved noncoding region 2), an enhancer region, is
important for Treg-cell lineage specification, as it enhances FoxP3
transcription ay allowing the binding of transcription factors [46].
These epigenetic control on FoxP3 expression cannot be determined
by splicing analysis alone.
In transplant field, in which self tolerance is crucial for successful
engraftment, it can be deduced that genetic variants or protein
expression level of FoxP3 not only affects graft outcome, but also
have potential as a therapeutic option. Based on this deduction, data
is accumulated in transplant field, mainly limited to hematopoietic
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stem cell transplantation in type 1 diabetes mellitus or IPEX
syndrome patients. For kidney transplant, accumulating data suggest
that Treg cells might induce graft tolerance in tertiary lymphoid
organ in graft, therefore slow down the kinetics of chronic rejection
[47]. In animal studies, mice and pigs show systemic tolerance to
kidney, skin and heart allografts from the same donor strain, initially
dependent on FoxP3+ cells [48, 49]. To lesser extent, the presence of
intragraft Tregs has been suggested as a positive predictor of
favorable transplant outcome in stable patients, especially with
subclinical signs of rejection [50]. However it is still controversial. Xu
X et al. conducted an experiment with chronic rejected kidney
allografts, showing it could be an epiphenomenon of the inflammatory
process [51]. In our study, no association was found between chronic
rejection and four SNPs studied, probably because we investigate
genetic polymorphism of Foxp3 only rather than afterward
transcription processes. Other regulating genes such as NFAT1 which
can affect the expression of Foxp3 and function of Tregs can play
some roles in graft tolerance.
Diabetic nephropathy (DN) composes only 5.2% (10/194) causes of
renal transplantation, which is much less compared to recent literature
[52, 53]. However, Han et al. reported that diabetes mellitus occupied
only 7.1% and 11.7% in 1995-1999 and 2000-2004 period, respectively,
and rushed after 2005 as causative disease of kidney
transplant-requiring ESRD patients [54]. Therefore our finding is
compatible in previous data in Korea taking account of the period of
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specimen collection. Recipients with primary DN experienced more
acute or any kinds of rejection episodes. However, small number of
DN recipients involved in this study makes this finding unreliable.
Boucek P et al. compared kidney transplant outcome between type2
DN (DN2) and non-type2 DN (non-DN) kidney recipients [55].
Although they found no significant difference in Kidney graft survival
between type 2 diabetic patients and non-diabetic controls (P = 0.19),
further investigation of the data suggests DN2 recipients show far
more rejection than non-DN recipients (8% vs. 3%, P value was not
available).
This study had some limitations. First, we did not performed the
expression level of FoxP3 or epigenetic change in FoxP3 neither in
blood or graft tissue. Second, three SNPs excluding rs2280883 showed
strong linkage disequilibrium so that we could not model SNP-SNP
interaction.
In conclusion, in our study we revealed the associations of
rs3761548AA genotype and rs2280883 CC genotype with inferior graft
survival in renal transplantation in Koreans. These findings may help
to elucidate the role of Tregs in renal transplantation and predict the
clinical outcome of renal allograft.
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서론: FoxP3은 동종이식편 관용유도에 중요한 조절T세포의 가장 신뢰
할 수 있는 표지자이다. FoxP3 유전자다형성이 신이식의 이식편생존과
연관되었다는 보고가 있어 이를 확인하고자 한다.
방법: 1996년부터 2004년까지 서울대학교병원에서 신이식을 시행한 성
인 환자 231례를 대상으로 4부위의 FoxP3 유전자다형성 (rs3761548
A/C, rs2280883C/T, rs5902434del/ATT, rs2232365A/G)을 염기서열특이
시발체를 이용한 중합효소연쇄반응(polymerase chain reaction with
sequence specific primers, PCR-SSP)를 이용하여 분석하였다.
결과: rs2280883 TT 유전형을 가진 환자들은 CC 혹은 CT 유전형을
가진 환자들에 비하여 유의하게 낮은 급성거부반응 발생을 보였다
(26.9% vs 53.3%, P = 0.038). rs3761548CC 유전형을 가진 환자들은
AC 혹은 AA 유전형을 가진 환자들에 비해 우수한 이식편생존을 나타
냈다(log rank test, P = 0.03). rs2280883 TT 유전형을 가진 환자들은
CC 혹은 CT 유전형을 가진 환자들에 비하여 우수한 이식편생존을 나
타냈다(P = 0.02). rs3761548CC 유전형을 가진 환자들은 AC 혹은 AA
유전형을 가진 환자들에 비해 낮은 원(原)사구체질환 재발율을 나타냈
다(P = 0.01).
결론: 한국인에서 FoxP3 유전자의 rs3761548 CC 유전자형과
rs2280883 TT 유전자형은 신이식의 우수한 임상성적과 상관관계가 있
었다.
………………………………………………………………………
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